24.04.2024
Binder Grösswang, together with Hengeler Mueller and Bär & Karrer, has advised private equity investor Trill Impact on a partnership with MedTech development and production company TT medic.
TT medic specialises in the development, production and cleanroom processing of high-quality polymer components for the life science industry. With locations in Germany, Austria and Switzerland, the company employs more than 150 people and, as a contract development and manufacturing organisation (CDMO), covers almost the entire value chain for clean room processing of high-quality polymer components.
Trill Impact was founded in 2019 and is an innovative investor with around EUR 1.2 billion assets under management across private equity, venture and microfinance investment strategies.
The core team of Binder Grösswang consisted of partner Philipp Kapl (lead), senior associate Mona Holzgruber as well as associates Florian Höllebauer and Christopher Marchel from the Corporate / M&A team. Further team members were counsel Sabine Apfl-Trompeter and associate Magdalena Schachinger (Employment Law), Senior associate David Rötzer and associate Tobias Haralter (Banking & Finance), counsel Hellmut Buchroithner and associate Florian Defrancesco (Intellectual Property and Information Technology), senior associate Christoph Raab (Competition Law), partner Regina Kröll, senior associate Anian Gruber and associate Armin Nimmrichter (Regulatory), associate Dario Schmelz (Dispute Resolution), partner Clemens Willvonseder and associate Manuela Wenger (Tax Law).
Binder Grösswang advised Trill Impact in an integrated team with Hengeler Müller (partner Daniel Möritz, senior associate Johannes Schmidt, associates Patrick Hell and Maximilian Mayer) and Bär & Karrer (partner Luca Jagmetti).